新闻通稿

主页/新闻通稿

Oramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China

Oramed has completed an analysis of its U.S.-based Phase 3 oral insulin trial with significant lowering of A1C levels seen in patient subgroups NEW YORK, May 15, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com) announced today that Hefei Tianhui Biotechnology Co. Ltd. [...]

2023-05-15T09:05:00+00:00分类:新闻通稿|标签:|

Oramed Appoints Ben Shapiro to its Board of Directors

NEW YORK, May 1, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) ("Oramed" or the "Company") (www.oramed.com) announced today the appointment of Mr. Benjamin Shapiro to its Board of Directors effective May 1, 2023. The Board determined that Mr. Shapiro qualifies as an independent director [...]

2023-05-01T16:45:00+00:00分类:新闻通稿|标签:|

Oramed Pharmaceuticals Issues Shareholder Update

NEW YORK, Feb. 9, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), announced today that it continues to conduct a comprehensive analysis of the data from its discontinued Phase 3 oral insulin trials.  In addition, management and the Board of Directors are [...]

2023-02-09T07:55:00+00:00分类:新闻通稿|标签:|

Oramed Announces Top-line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes

NEW YORK, Jan. 11, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced today top-line results from its Phase 3 randomized, double-blind, placebo-controlled, multicenter clinical trial (ORA-D-013-1) comparing the efficacy of ORMD-0801 [...]

2023-01-11T20:00:00+00:00分类:新闻通稿|标签:|

Oramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASH

Achieved primary endpoint of safety and tolerability in participants with Type 2 diabetes with NASH. Oral insulin candidate demonstrates consistent trends across key secondary endpoints with reduction of liver fat, liver stiffness and lipids. Key opinion leaders' discussion highlights new data and is available on [...]

2022-11-17T12:26:00+00:00分类:新闻通稿|标签:|